B cell receptor signaling in chronic lymphocytic leukemia.
Jan A. Burger,Nicholas Chiorazzi +1 more
Reads0
Chats0
TLDR
The evolution of this field is discussed, from BCR-related prognostic markers, to mechanisms of BCR activation, and targeting of B CR-associated kinases, the emerging Achilles' heel in CLL pathogenesis.About:
This article is published in Trends in Immunology.The article was published on 2013-12-01 and is currently open access. It has received 378 citations till now. The article focuses on the topics: B-cell receptor & Chronic lymphocytic leukemia.read more
Citations
More filters
Journal ArticleDOI
LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia
Phuong-Hien Nguyen,Oleg Fedorchenko,Natascha Rosen,Maximilian Koch,Romy Barthel,Tomasz Winarski,Alexandra Florin,F. Thomas Wunderlich,Nina Reinart,Michael Hallek +9 more
TL;DR: It is demonstrated that LYN kinase is essential for CLL progression and syngeneic CLL transplantation of CLL cells into Lyn- or Btk-deficient recipients results in a strongly delayed leukemic progression and prolonged survival.
Journal ArticleDOI
Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.
Adam Burns,Reem Alsolami,Reem Alsolami,Reem Alsolami,Jennifer Becq,Basile Stamatopoulos,Adele Timbs,David Bruce,Pauline Robbe,Pauline Robbe,Dimitris Vavoulis,Dimitris Vavoulis,Ruth Clifford,Maite Cabes,Helene Dreau,Jenny C. Taylor,Knight Sjl.,Robert Månsson,David Bentley,Renée Beekman,J I Martín-Subero,E. Campo,Richard S. Houlston,Kate Ridout,Kate Ridout,Anna Schuh,Anna Schuh +26 more
TL;DR: The hypothesis that differences in clinical outcome and biological characteristics between the two subgroups might reflect differences in mutation distribution, incidence and distinct underlying mutagenic mechanisms is supported.
Journal ArticleDOI
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Philip A. Thompson,Jan A. Burger +1 more
TL;DR: Ibrutinib is effective in both low- and high-risk CLL patients, achieving durable remissions with continuous therapy in the majority of patients, and second-generation BTK inhibitors are being developed, with different and generally more BTK-selective kinase inhibition profiles, which may increase the safety and/or efficacy.
Journal ArticleDOI
Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia.
Nikos Papakonstantinou,Stavroula Ntoufa,Elisavet Chartomatsidou,Giorgio L. Papadopoulos,Artemis G. Hatzigeorgiou,Achiles Anagnostopoulos,Katerina Chlichlia,Paolo Ghia,Marta Muzio,Chrysoula Belessi,Kostas Stamatopoulos +10 more
TL;DR: Specific miRNAs differentially expressed among CLL subgroups with distinct BcR and/or TLR signaling may modulate the biological and clinical behavior of the CLL clones.
Book ChapterDOI
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
Klaus Okkenhaug,Jan A. Burger +1 more
TL;DR: The central role of PI3Ks in mediating signals from the B cell receptor that not only facilitate the development of functional B cell repertoire, but also support the growth and survival of neoplastic B cells are reviewed, focusing on chronic lymphocytic leukemia (chronic lymphocytics leukemia (CLL)) B cells.
References
More filters
Journal ArticleDOI
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Terry J. Hamblin,Zadie Davis,Zadie Davis,Anne Gardiner,Anne Gardiner,David G. Oscier,David G. Oscier,Freda K. Stevenson,Freda K. Stevenson +8 more
TL;DR: In this paper, the authors sequenced the Ig V(H) genes of the tumor cells of 84 patients with CLL and correlated their findings with clinical features, finding that the lack of somatic mutation and trisomy 12 was associated with a less favorable prognosis.
Journal ArticleDOI
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Rajendra N. Damle,Tarun Wasil,Tarun Wasil,Tarun Wasil,Franco Fais,Franco Fais,Franco Fais,Fabio Ghiotto,Fabio Ghiotto,Fabio Ghiotto,Angelo Valetto,Angelo Valetto,Angelo Valetto,Steven L. Allen,Steven L. Allen,Steven L. Allen,Aby Buchbinder,Aby Buchbinder,Aby Buchbinder,Daniel R. Budman,Daniel R. Budman,Daniel R. Budman,Klaus Dittmar,Klaus Dittmar,Klaus Dittmar,Jonathan E. Kolitz,Jonathan E. Kolitz,Jonathan E. Kolitz,Stuart M. Lichtman,Stuart M. Lichtman,Stuart M. Lichtman,Philip Schulman,Philip Schulman,Philip Schulman,Vincent Vinciguerra,Vincent Vinciguerra,Vincent Vinciguerra,Kanti R. Rai,Kanti R. Rai,Kanti R. Rai,Manlio Ferrarini,Manlio Ferrarini,Manlio Ferrarini,Nicholas Chiorazzi,Nicholas Chiorazzi,Nicholas Chiorazzi +45 more
TL;DR: In this paper, cellular immunophenotypic studies were performed on a cohort of randomly selected IgM(+) B-chronic lymphocytic leukemia (B-CLL) cases for which Ig V(H) and V(L) gene sequences were available.
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more
TL;DR: Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.
Journal ArticleDOI
Chronic lymphocytic leukemia.
TL;DR: From the Institute for Medical Research, North Shore–LIJ Health System (N.R.R.), and the Departments of Medicine, North shore University Hospital, Manhasset, N.Y. (K.C., K.R.) and the Dipartimento di Oncologia Clinica e Sperimentale, Universitá di Genova (M.F.).
Journal ArticleDOI
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis,Vu N. Ngo,Georg Lenz,Pavel Tolar,Ryan M. Young,Paul B. Romesser,Holger Kohlhammer,Laurence Lamy,Hong Zhao,Yandan Yang,Weihong Xu,Arthur L. Shaffer,George E. Wright,Wenming Xiao,John Powell,Jian Kang Jiang,Craig J. Thomas,Andreas Rosenwald,German Ott,Hans K. Müller-Hermelink,Randy D. Gascoyne,Joseph M. Connors,Nathalie A. Johnson,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Wyndham H. Wilson,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Dennis D. Weisenburger,Wing C. Chan,Susan K. Pierce,Louis M. Staudt +36 more
TL;DR: Findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.
Related Papers (5)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman,Jeff P. Sharman,Steven Coutre,Bruce D. Cheson,John M. Pagel,Peter Hillmen,Jacqueline C. Barrientos,Andrew D. Zelenetz,Thomas J. Kipps,Ian W. Flinn,Paolo Ghia,Herbert Eradat,Thomas J. Ervin,Nicole Lamanna,Bertrand Coiffier,Andrew R. Pettitt,Shuo Ma,Stephan Stilgenbauer,Paula Cramer,Maria Aiello,Dave Johnson,Langdon L. Miller,Daniel Li,Thomas Jahn,Roger Dansey,Michael Hallek,Susan O'Brien +26 more
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C. Byrd,Jennifer R. Brown,Susan O'Brien,Jacqueline C. Barrientos,Neil E. Kay,Nishitha Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,S Devereux,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Christopher Pocock,Patrick Thornton,Federico Caligaris-Cappio,Tadeusz Robak,Julio Delgado,Stephen J. Schuster,Marco Montillo,Anna Schuh,S. de Vos,Devinder Gill,Adrian Bloor,Claire Dearden,Carol Moreno,Jeffrey Jones,Alvina D. Chu,Maria Fardis,Jesse McGreivy,Fong Clow,Danelle F. James,Peter Hillmen +34 more